{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:03:18Z","timestamp":1770433398629,"version":"3.49.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.pupt.2009.10.002","type":"journal-article","created":{"date-parts":[[2009,10,24]],"date-time":"2009-10-24T08:54:39Z","timestamp":1256374479000},"page":"135-144","source":"Crossref","is-referenced-by-count":43,"title":["The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data"],"prefix":"10.1016","volume":"23","author":[{"given":"M.","family":"Cazzola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Floriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.P.","family":"Page","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2009.10.002_bib1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1440-1843.2002.00399.x","article-title":"Worldwide guidelines for chronic obstructive pulmonary disease: a comparison of diagnosis and treatment recommendations","volume":"7","author":"Iqbal","year":"2002","journal-title":"Respirology"},{"key":"10.1016\/j.pupt.2009.10.002_bib2","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1378\/chest.123.3.784","article-title":"Costs of chronic bronchitis and COPD. A one year follow-up study","volume":"123","author":"Miravitlles","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2009.10.002_bib3","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"The relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"55","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2009.10.002_bib4","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","article-title":"Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease","volume":"157","author":"Seemungal","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2009.10.002_bib5","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1378\/chest.121.5.1449","article-title":"Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD","volume":"121","author":"Miravitlles","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2009.10.002_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1164\/rccm.200603-381OC","article-title":"Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm","volume":"175","author":"de Marco","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2009.10.002_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1164\/rccm.200706-820ED","article-title":"Airway inflammation in COPD. Friend or foe?","volume":"176","author":"Brusasco","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2009.10.002_bib8","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","article-title":"Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"176","author":"Rabe","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2009.10.002_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/17476348.1.3.307","article-title":"Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease","volume":"1","author":"Moretti","year":"2007","journal-title":"Expert Rev Resp Med"},{"key":"10.1016\/j.pupt.2009.10.002_bib10","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomized controlled trials: the QUORUM statement","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2009.10.002_bib11","first-page":"612","article-title":"Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxicillin as basic treatment (ECOBES, european chronic obstructive bronchitis erdosteine study)","volume":"33","author":"Marchioni","year":"1995","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.pupt.2009.10.002_bib12","first-page":"521","article-title":"\u00c9tude multicentrique, control\u00e9e, en double aveugle, de l'efficacit\u00e9 et de la tol\u00e9rance de vectrine\u00ae 8erdost\u00e9ine) versus placebo dans le traitement de la bronchite chronique hypersecr\u00e9tante stabilis\u00e9e","volume":"16","author":"Aubier","year":"1999","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.pupt.2009.10.002_bib13","unstructured":"Arnaud A. Clinical study of efficacy and tolerability of erdosteine in the treatment of chronic obstructive bronchitis with superinfection. Controlled double-blind study vs. N-acetylcysteine. Clinical Study Report EC\/ER9022P, Data on File 1991. Partly published in: Mancini C. Erdosteine, the second generation mucolytic: international up-dating of clinical studies (adults and paediatrics)."},{"key":"10.1016\/j.pupt.2009.10.002_bib14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/thx.43.8.585","article-title":"Influence of erdosteine, a mucolytic agent, on amoxicillin penetration into sputum in patients with an infective exacerbation of chornic bronchitis","volume":"43","author":"Ricevuti","year":"1988","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2009.10.002_bib15","first-page":"171","article-title":"Erdosteine or placebo combined with co-trimoxazole in the treatment of hypersecretive infectious bronchitis: a double blind clinical trial","volume":"12","author":"Hotzinger","year":"1991","journal-title":"Med Praxis"},{"key":"10.1016\/j.pupt.2009.10.002_bib16","unstructured":"Ginesu F. Controlled clinical trial vs. ambroxol. Clinical Study Report FARMO 83\/R, Data on File; 1989."},{"key":"10.1016\/j.pupt.2009.10.002_bib17","first-page":"207","article-title":"Erdosteine versus N-Acetylcysteine in the treatment of exacerbation of chronic bronchopneumopathies: A double blind clinical trial","volume":"12","author":"Zanasi","year":"1991","journal-title":"Med Praxis"},{"key":"10.1016\/j.pupt.2009.10.002_bib18","first-page":"101","article-title":"Controlled clinical study of erdosteine in chronic bronchitis patients","volume":"47","author":"Franco","year":"1995","journal-title":"Arch Med Interna"},{"key":"10.1016\/j.pupt.2009.10.002_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.pupt.2009.10.002_bib20","doi-asserted-by":"crossref","first-page":"L 557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"10.1016\/j.pupt.2009.10.002_bib21","series-title":"Systematic reviews in health care. Meta-analysis in context","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","author":"Deeks","year":"2001"},{"key":"10.1016\/j.pupt.2009.10.002_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02719705","article-title":"Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease","volume":"168","author":"Marchioni","year":"1990","journal-title":"Lung"},{"key":"10.1016\/j.pupt.2009.10.002_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000195904","article-title":"Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis","volume":"58","author":"Olivieri","year":"1991","journal-title":"Respiration"},{"key":"10.1016\/j.pupt.2009.10.002_bib24","unstructured":"Grandi M, Zucchi L. A dose effect study of oral erdosteine on rheologic properties of human mucus. Randomised double-blind study with comparison among 3 groups treated with 600 and 900mg of erdosteine or with placebo. Data on File; 1993."},{"key":"10.1016\/j.pupt.2009.10.002_bib25","first-page":"159","article-title":"A dose effect study of oral erdosteine on rheological properties of human mucus","volume":"12","author":"Siquet","year":"1991","journal-title":"Med Praxis"},{"key":"10.1016\/j.pupt.2009.10.002_bib26","unstructured":"Nagaoka S. Early phase II trial of KW-9144 on sputum excretion difficulty. Open study with comparison among three doses: 300, 600 and 900mg\/day. Data of File; 1993."},{"key":"10.1016\/j.pupt.2009.10.002_bib27","unstructured":"Inclimona V. Therapeutic clinical trial with FARMO 83\/R: Open design. Data on File; 1985."},{"key":"10.1016\/j.pupt.2009.10.002_bib28","unstructured":"Cattini G. Efficacy and safety of erdosteine in chronic bronchitis in phase of clinical reactivation: open study. Data on File; 1991."},{"key":"10.1016\/j.pupt.2009.10.002_bib29","unstructured":"Deodato M. Clinical evaluation of the efficacy and tolerability of erdosteine (450mg\/die per aerosol): open study in the treatment of chronic bronchitis in phase of clinical reactivation. Data on File; 1991."},{"key":"10.1016\/j.pupt.2009.10.002_bib30","first-page":"481","article-title":"Efficacy and tolerability of erdosteine in chronic obstructive pulmonary disease","volume":"57","author":"de Castro Pereira","year":"2000","journal-title":"Rev Bras Med"},{"key":"10.1016\/j.pupt.2009.10.002_bib31","first-page":"308","article-title":"Effect of erdosteine in patients suffering from chronic obstructive pulmonary disease","volume":"9\u201310","author":"Rozborilova","year":"2002","journal-title":"Slov Lek"},{"key":"10.1016\/j.pupt.2009.10.002_bib32","first-page":"219","article-title":"Prevention of exacerbations in chronic bronchitic patients with erdosteine","volume":"12","author":"Fioretti","year":"1991","journal-title":"Med Praxis"},{"key":"10.1016\/j.pupt.2009.10.002_bib33","first-page":"113","article-title":"Cross-over clinical study of efficacy and tolerability of erdosteine in the treatment of chronic obstructive bronchial disease in stable hypersecretive phase controlled double-blind study vs placebo","volume":"47","author":"Ghiringhelli","year":"1995","journal-title":"Arch Med Interna"},{"key":"10.1016\/j.pupt.2009.10.002_bib34","first-page":"143","article-title":"The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the equalife study","volume":"30","author":"Moretti","year":"2004","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.pupt.2009.10.002_bib35","unstructured":"Rossi F. Clinical evaluation of safety and efficacy of erdosteine (450mg\/die per aerosol): double-blind study vs. N-acetylcysteine in the treatment of chronic bronchopneumopathy in phase of clinical reactivation. Data on File; 1991."},{"key":"10.1016\/j.pupt.2009.10.002_bib36","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.4046\/trd.1997.44.6.1296","article-title":"Clinical efficacy of erdosteine in patients with acute or chronic bronchitis: a randomized, double-blind, comparative study vs. ambroxol","volume":"44","author":"Kim","year":"1997","journal-title":"Tuberc Respir Dis"},{"key":"10.1016\/j.pupt.2009.10.002_bib37","first-page":"35","article-title":"Evaluation of efficacy and safety of erdosteine in patients affected by exacerbation of chronic bronchitis and receiving ciprofloxacin as basic treatment","volume":"4","author":"Mohanty","year":"2001","journal-title":"J Clin Res"},{"key":"10.1016\/j.pupt.2009.10.002_bib38","first-page":"183","article-title":"Erdosteine: original secretolytic drug with mucociliar activity. A\u00a0controlled clinical study versus ambroxol","volume":"12","author":"Tellings","year":"1991","journal-title":"Med Praxis"},{"key":"10.1016\/j.pupt.2009.10.002_bib39","first-page":"89","article-title":"Mucolytic activity of erdosteine: double blind clinical trial vs. placebo","volume":"47","author":"Bisetti","year":"1995","journal-title":"Arch Med Interna"},{"key":"10.1016\/j.pupt.2009.10.002_bib40","unstructured":"Voisin C. Controlled, double-blind, pilot study comparing erdosteine at the daily dose of 600mg to placebo in two groups of patients affected by stabilized chronic obstructive bronchitis. Clinical Study Report HEC\/ERD\/8903P, Data on File; 1990."},{"key":"10.1016\/j.pupt.2009.10.002_bib41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1034\/j.1399-3003.2000.16b12.x","article-title":"The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review","volume":"16","author":"Stey","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2009.10.002_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001287.pub2","article-title":"Mucolytic agents for chronic bronchitis or chornic obstructive pulmonary disease (Review)","author":"Poole","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pupt.2009.10.002_bib43","unstructured":"Marchioni CF. Clinical experience with erdosteine in the treatment of exacerbation of chronic obstructive bronchopneumopathies. Clinical study report FER\/05\/C300\/01, Data on File; 1987."},{"key":"10.1016\/j.pupt.2009.10.002_bib44","unstructured":"Scarpazza G. Controlled clinical trial of erdosteine in chronic bronchitis under exacerbation. Clinical study report FER\/05\/C150\/01, Data on File; 1987."},{"key":"10.1016\/j.pupt.2009.10.002_bib45","first-page":"299","article-title":"Erdosteine: a new molecule with mucolytic activity. Clinical and instrumental evaluation in patients with acute exacerbated chronic bronchopneumopathies","volume":"42","author":"Fumagalli","year":"1988","journal-title":"It J Chest Dis"},{"key":"10.1016\/j.pupt.2009.10.002_bib46","unstructured":"Materazzi F. Evaluation of efficacy and safety of erdosteine in chronic bronchitis in phase of clinical reactivation. Clinical study report EP\/S05\/C300\/0590, Data on File; 1991."},{"key":"10.1016\/j.pupt.2009.10.002_bib47","first-page":"197","article-title":"Erdosteine: evaluation of mucorheological and immunosecretory parameters in patients with bronchial phlogistic pathology","volume":"12","author":"Busin","year":"1991","journal-title":"Med Praxis"},{"issue":"Suppl.III","key":"10.1016\/j.pupt.2009.10.002_bib48","first-page":"A47","article-title":"Fast onset of antioxidant actions of erdosteine and its potential use for acute treatment of COPD exacerbations","volume":"62","author":"Kharitonov","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2009.10.002_bib49","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1378\/chest.121.4.1058","article-title":"Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral slow-release theophylline in the treatment of COPD","volume":"121","author":"Rossi","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2009.10.002_bib50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/ formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2009.10.002_bib51","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2009.10.002_bib52","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1378\/chest.124.6.2182","article-title":"The breathlessness, cough, and sputum scale: the development of empirically based guidelines for interpretation","volume":"124","author":"Kline Leidy","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2009.10.002_bib53","doi-asserted-by":"crossref","first-page":"238S","DOI":"10.1378\/chest.129.1_suppl.238S","article-title":"Cough suppressant and pharmacologic protussive therapy. ACCP evidence-based clinical practice guidelines","volume":"129","author":"Bolser","year":"2006","journal-title":"Chest"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553909001084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553909001084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T10:26:55Z","timestamp":1558607215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553909001084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S1094553909001084"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2009.10.002","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}